Phenobarbital
Total Payments
$1.1M
Transactions
54
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $650,013 | 35 | 1 |
| 2022 | $215,109 | 13 | 0 |
| 2021 | $21,650 | 2 | 0 |
| 2019 | $156,998 | 3 | 0 |
| 2017 | $8,933 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 53 | 99.8% |
| Consulting Fee | $2,064 | 1 | 0.2% |
Payments by Type
Research
$1.1M
53 transactions
General
$2,064
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phenobarbital Neonate Study Phase III | Hikma Pharmaceuticals USA | $618,752 | 0 |
| Efficacy and Safety of Intra. Phenobarbital in Neonatal Seizures | Hikma Pharmaceuticals USA | $298,894 | 0 |
| Study to Assess the Efficacy and Safety of Intra. Phenobarbital in Neonatal Seizures | Hikma Pharmaceuticals USA | $124,059 | 0 |
| Phenobarbital Oral Phase IV | West-Ward Pharmaceuticals | $8,933 | 0 |
Top Doctors Receiving Payments for Phenobarbital
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bonita Springs, FL | $1.1M | 53 |
| , DO | Neonatal-Perinatal Medicine | Rochester, NY | $2,064 | 1 |
Ad
Manufacturing Companies
- Hikma Pharmaceuticals USA $1.0M
- West-Ward Pharmaceuticals $8,933
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 1
- Transactions 54
About Phenobarbital
Phenobarbital is a drug associated with $1.1M in payments to 1 healthcare providers, recorded across 54 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2017 to 2023. In 2023, $650,013 was paid across 35 transactions to 1 doctors.
The most common payment nature for Phenobarbital is "Unspecified" ($1.1M, 99.8% of total).
Phenobarbital is associated with 4 research studies, including "Phenobarbital Neonate Study Phase III" ($618,752).